Showing results (161-170 of 186) with videos related to

Sort By:
Pageof 19
Emerging Microbes & Infections|May 27, 2024
Emergence and ongoing outbreak of ST80 vancomycin-resistant Enterococcus faecium in Guangdong province, China from 2021 to 2023: a multicenter, time-series and genomic epidemiological studyCong Shen, Li Luo, Hongyun Zhou, et al.
BMC Cancer|August 11, 2023
First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort studyKaili Zhong, Yanyan Shi, Yuhuan Gao, et al.
International Journal of Medical Microbiology : IJMM|June 1, 2025
Occurrence of vanA/vanM-positive vancomycin-resistant Enterococcus faecium in hospital wastewater associated with clinical infections in Guangzhou, China: A genomic epidemiological studyLiling Zhang, Minxuan Su, Shaowei Meng, et al.
Cancer Medicine|April 19, 2022
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter studyYuchen Zhang, Panpan Liu, Jun Cai, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Depression of reactivity by the collision energy in the single barrier H + CD4 -> HD + CD3 reactionWeiqing Zhang, Yong Zhou, Guorong Wu, et al.
Haematologica|September 5, 2024
Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trialNingjing Lin, Xiuhua Sun, Hui Zhou, et al.
Npj Mental Health Research|March 25, 2026
Exploratory characterization of gut microbiota and cognitive profiles in adolescents with subthreshold depression: a shotgun metagenomics sequencing studyRunhua Wang, Rong Ma, Yuanyuan Cai, et al.
Blood Cancer Journal|March 18, 2026
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)Juying Wei, Qingqing Cai, Liling Zhang, et al.
Signal Transduction and Targeted Therapy|May 16, 2024
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II studyYan Gao, Haixia He, Xueping Li, et al.
Frontiers in Oncology|March 15, 2021
Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative GroupWeiping Liu, Yong Yang, Shunan Qi, et al.
Pageof 19